ENGIE North America has secured a nine-year contract to supply renewable energy to AstraZeneca, a Coppell-based company, ...

AstraZeneca receives FDA approval for Koselugo to treat adults with NF1 and inoperable plexiform neurofibromas, backed by ...

AstraZeneca's hopes for baxdrostat are high, as in early 2023 it acquired the drug by purchasing its developer -- biotech ...

The pharmaceutical company argues it is protected from any and all claims under the congressionally approved Public Readiness and Emergency Preparedness Act.

Fueled by gains in all of its therapeutic areas, the company had a triumphant third quarter.

Shares in AstraZeneca rose past their September 2024 peak on Tuesday, hitting a fresh record high and cementing the company's ...

The FDA’s Office of Prescription Drug Promotion (OPDP) issued an Untitled Letter, backdated to September 23, to Tracey M. Henderson, MS, MBA – AstraZeneca’s promotional regulatory affairs review ...

AstraZeneca is the stock to beat in the United Kingdom. The global pharmaceutical company saw its stock rise to its all-time ...

AstraZeneca is moving ahead with a major build-out of its American footprint, tying a new facility to a broader $3.5 billion push in research and manufacturing across the United States. The company ...

In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based ...